MedMe Health vs Fortuna Health

About

MedMe Health is a pharmacy clinical services platform that helps pharmacists schedule, conduct, document, and bill for clinical services at scale — enabling pharmacies to systematically deliver services including medication prescribing and adaptation, point-of-care testing (COVID, flu, strep), vaccination programs, and chronic condition monitoring appointments, rather than managing these services ad hoc. Founded in the late 2010s in Toronto, Canada and a Y Combinator W21 graduate, MedMe Health is backed by Microsoft's M12 venture fund and has scaled to 1,100+ pharmacies across Canada.\n\nMedMe's platform provides pharmacists with appointment scheduling tools for clinical service bookings (which can be patient-initiated or provider-referred), structured clinical service workflows that guide pharmacists through each service type, documentation templates, and billing integration with provincial health authorities and insurance plans. The platform makes it practical for pharmacy chains and independent pharmacies to operate as clinical service providers at scale — without practice management software, the administrative overhead of offering multiple clinical services is prohibitive.\n\nIn 2025, MedMe Health operates at the intersection of pharmacy technology and primary care expansion — Canadian provincial governments have significantly expanded pharmacist scope of practice, allowing pharmacists to prescribe for minor ailments, adapt medications, and provide more comprehensive care services. MedMe competes with RxNT, PioneerRx, and existing pharmacy management system vendors adding clinical service modules for pharmacy practice management. The expansion of pharmacist scope of practice across Canadian provinces creates strong market tailwinds as pharmacies invest in the technology to capture revenue from newly billable services. The 2025 strategy focuses on deepening provincial billing integrations, growing with pharmacy chains implementing standardized clinical programs, and expanding to US pharmacies as scope of practice policies evolve.